转自：智通财经 在当下竞争激烈且不断变革的医药零售市场中，大参林（维权）医药集团股份有限公司（603233.SH） 作为行业龙头，凭借稳健的经营策略与积极的创新探索，在 2024 年及 2025 年第一季度持续书写着业绩 增长的优异答卷，同时其在大健康产业的深度布局，更为长远的可持续发展筑牢根基。 2024年业绩回顾：营收稳健上扬 门店增速攀升 2024 年，大参林全年实现营业收入 264.97 亿元，较上一年度同比增长 8.01%，这一成绩的背后，是公 司在门店拓展、运营优化以及市场深耕等多方面协同发力的成果。秉持 "深耕华南，布局全国" 的核心 战略，大参林通过 "自建 + 并购 + 直营式加盟" 三驾马车齐驱并进，不断拓展市场版图。截至 2024 年 末，全国门店总数攀升至 16553 家，2024 年内净增门店高达 2479 家 ，密集的门店网络不仅提高了品牌 曝光度，更为营收增长源源不断地输送动力。 从区域维度剖析，2024 年公司在华南地区、华中地区、华东地区、东北、华北西南及西北地区营业收 入均实现同比增长。其中，东北、华北、西南及西北地区增速尤为亮眼，达 34.42%，成为公司营收增 长的新引 ...

Core Viewpoint - Junyao Health has reported significant growth in its probiotic beverage and food business, positioning itself as a leader in the health industry with a focus on innovation and international expansion [1][2][6] Financial Performance - In 2024, Junyao Health achieved a revenue of 1.458 billion yuan, while the first quarter of 2025 saw revenue of 401 million yuan [1] - The probiotic beverage and food segment generated a total revenue of 792 million yuan in 2024, with a remarkable year-on-year growth of 139.19% in the first quarter of 2025 [2] Market Trends - The probiotic market in China is rapidly expanding, with a compound annual growth rate of 14% from 2018 to 2022, growing from 64.77 billion yuan to approximately 109.38 billion yuan [2] - Global probiotic industry value is expected to exceed 77 billion USD by 2025, with China accounting for over 25% of the market share [2] R&D and Innovation - Junyao Health emphasizes the importance of independent research and development, establishing a comprehensive "R&D-production-sales" integrated chain [2][3] - The subsidiary Junyao Runying has developed a resource library of over 30,000 probiotic strains and collaborates with several universities to enhance innovation [3] Supply Chain and Distribution - The company has expanded its e-commerce channels, achieving a staggering 1173.33% year-on-year growth in online sales in the first quarter of 2025 [2] - Junyao Health has established a comprehensive supply chain model, integrating raw materials, products, and distribution channels [3][4] International Expansion - In 2024, Junyao Health's international business generated approximately 84.6 million yuan, reflecting a year-on-year growth of 24.54%, with a 77.43% increase in the first quarter of 2025 [5] - Junyao Runying is recognized as a major probiotic production base in Asia, exporting to over 80 countries and regions [5] Policy and Market Outlook - The national initiative to promote "Weight Management Year" is expected to further boost the health industry, providing a favorable environment for Junyao Health's growth [6] - With its leading position in the ambient yogurt market and a comprehensive probiotic strategy, Junyao Health is well-positioned for sustained growth in the health industry [6]

Core Viewpoint - The Chinese government is promoting a "Weight Management Year" initiative, which is expected to significantly boost the health industry, potentially exceeding a trillion yuan in market size. This creates a favorable environment for companies like Junyao Health, which is focusing on expanding its leadership in the probiotic market and enhancing its product offerings [1][2]. Group 1: Company Performance - Junyao Health reported revenues of approximately 1.458 billion yuan for 2024 and 401 million yuan for the first quarter of 2025, with a notable 139.19% increase in probiotic food revenue in Q1 2025 [1][3][4]. - The company achieved a gross margin of 38.39% in 2024, an increase of 1.98% from the previous year, attributed to reduced raw material costs and optimized operational management [3][4]. Group 2: Market Trends - The health industry in China is projected to reach a market size of 13.4 trillion yuan by 2025 and further grow to 29.1 trillion yuan by 2030, driven by the "Healthy China 2030" strategy [2]. - The probiotic market in China has seen significant growth, with a compound annual growth rate of 14% from 2018 to 2022, increasing from 64.77 billion yuan to approximately 109.38 billion yuan [5]. Group 3: Product Development - Junyao Health is expanding its product line to include low-temperature active probiotic beverages, leveraging innovative fermentation technology and developing functional beverages that combine probiotics with other beneficial ingredients [2][4]. - The company has developed a diverse range of health functional beverages, including products targeting beauty, eye health, sleep, and nutrition, to meet various consumer health needs [2][4]. Group 4: Strategic Initiatives - Junyao Health is enhancing its research and development capabilities by integrating with leading companies in the probiotic sector, establishing a comprehensive "R&D-production-sales" integrated system to strengthen its market position [6][7]. - The company is expanding its e-commerce presence, with a significant increase in online sales, particularly in the first quarter of 2025, where e-commerce revenue surged by 1,173.33% [4][8]. Group 5: International Expansion - Junyao Health's international business achieved revenue of approximately 84.6 million yuan in 2024, a year-on-year increase of 24.54%, with Q1 2025 showing a remarkable growth of 77.43% [9]. - The company exports to over 80 countries and regions, positioning itself as a leading exporter of probiotics in China, benefiting from competitive pricing and stable supply chains [9]. Group 6: Future Outlook - With the release of production capacity, strengthened technological barriers, and expanded brand influence, Junyao Health is expected to continue leading the health industry and achieve long-term stable growth [10].

以岭药业 20250429 摘要 • 以岭药业 2025 年一季度营收 23.58 亿元，同比下降 6.5%，归母净利润 3.26 亿元，同比增长 7.25%，经营性净现金流 3.4 亿元，同比增长 190%。应收账款周转天数同比下降 35 天，经营质量初步提升。 • 连花清瘟产品一季度销售同比增长近 30%，心脑血管处方药受政策影响有 所下滑，但预计二季度将逐步恢复性增长。二线品种如静神胶囊、复方丹 参片等开户工作稳步推进，OTC 品种八子补肾胶囊加大推广力度。 • 健康科技板块重点推广蓝帽子保健食品及功能性植物饮料，怡梦饮料单品 销售超 1.2 亿，调节血糖饮料精力旺销售额超 5,000 万，市场前景良好。 • 公司研发方面，治疗糖尿病视网膜病变的明目胶囊进入医保，治疗过敏性 鼻炎的芪芳鼻通片获批上市，六个品种处于临床阶段，小儿连花清瘟颗粒 处于三期临床。五项循证医学研究成果发表在国际顶刊。 • 化学生物板块有四个创新药进入临床阶段，多个一类创新药处于临床前验 证阶段，百乐宁已报产，SY0,206 片用于急性髓性白血病治疗已进入三期 临床研究。 Q&A 2024 年以岭药业的营业收入和净利润情况如何？ 2 ...

Core Viewpoint - Han Commercial Group (600774.SH) reported a revenue of 1.175 billion yuan for 2024, a decrease of 15.41% year-on-year, primarily due to market fluctuations and policy adjustments in the medical sector [1] Group 1: Financial Performance - The company experienced a revenue decline attributed to the medical sector's income reduction caused by market environment changes and policy adjustments [1] - The company anticipates a recovery in performance by 2025 as it deepens its "Big Health + Big Business" dual main business strategy [1] Group 2: Pharmaceutical Sector - Han Commercial Group has expanded its presence in the big health sector, focusing on chemical drugs, traditional Chinese medicine, and medical devices through its subsidiary, Dikon Pharmaceutical [2] - The company invested over 50 million yuan in R&D for 2024, emphasizing innovation and product development [1] - The company holds complete intellectual property rights for its global Class I innovative drug DDCI-01, which has completed Phase II clinical trials and is entering Phase III for indications related to pulmonary arterial hypertension and benign prostatic hyperplasia [1] Group 3: Traditional Chinese Medicine - The company is progressing with the resumption of production for Dikon Traditional Chinese Medicine following the bankruptcy restructuring of Dongfang Pharmaceutical, achieving the market launch of 13 products [2] - The star product, Tongqiao Bi Yan Granules, sold over 13 million boxes in 2024, marking a 20% increase year-on-year [2] Group 4: Medical Devices - Dikon Zhongke, a subsidiary, has seen growth in its absorbable medical devices, including absorbable bone fixation screws and membranes, with successful bids in various provinces [2] - The company is advancing the development of new medical devices, obtaining multiple registration certificates and inspection approvals [2] Group 5: Assisted Reproductive Technology - The company plans to enhance support for key disciplines in assisted reproduction, aiming to establish a well-known specialty hospital in the field [2] Group 6: Commercial Exhibition Sector - The company is adapting its shopping centers and business operations to market changes, exploring new business models such as low-altitude logistics [3] - The transformation of the former Wuhan wedding photo material city into the Han Chao Z6 project aims to attract a younger demographic [3] - The Wuhan International Exhibition Center is undergoing operational upgrades to create a new service model for the exhibition industry [3] Group 7: Future Strategy - The company aims to strengthen its pharmaceutical sector by focusing on traditional Chinese medicine, enhancing sales, and driving R&D [3] - The commercial sector will focus on precise positioning and upgrading to enhance profitability and invigorate traditional brands [3]

中华全国总工会成立100周年暨全国劳动模范和先进工作者表彰大会 87 : 84 Inter so # 1 (ST 01 周云杰 周云杰，海尔集团党委书记、董事局主席、首席执行官，正高级工程师，2025年"全国劳动模范"。曾 获"全国五一劳动奖章""全国优秀共产党员""山东省省长质量奖""中国经济新闻人物"等荣誉。 自1988年加入青岛电冰箱总厂，周云杰37年如一日深耕制造业，参与并加速推进了海尔从传统制造企业 转型为物联网生态品牌生态品牌。在他的引领下，海尔在智慧住居领域带动产业"高端化、智能化、绿 色化、集群化"升级，布局大健康、产业互联网等新兴领域。 周云杰深耕制造主业，推动家电产业"高端化、智能化、绿色化、集群化"升级，增强自主品牌国际竞争 力。以高端品牌创造高品质生活，海尔旗下卡萨帝品牌实现7年增长13倍，成为轻工行业唯一一个单价 及销量全面超越欧美品牌的中国品牌；海外市场坚持自主创牌，海外销售的中国品牌家电每10台中有6 台是海尔贡献的，为"中国制造"向"中国品牌"转型提供示范路径。 智能化转型中，周云杰以大规模定制重塑制造模式，推动国内工厂制造费率优化4%,人均效率提升 16%。2020年，他首创 ...

Core Viewpoint - The company faces performance pressure due to a deep adjustment in the real estate industry, leading to mixed results in revenue and profit for 2024 [2][3]. Financial Performance - The company reported a revenue of approximately 8.73 billion yuan, a year-on-year increase of 0.59%, while net profit attributable to shareholders was about 322 million yuan, a decline of 24.84% [2]. - Operating cash flow decreased by 37.2% to approximately 787 million yuan, and basic earnings per share fell by 23.42% to 0.85 yuan [2]. - Revenue from soft beds and related products dropped by 8.39% to 2.44 billion yuan, and sofa business revenue decreased by 6.55% to 719 million yuan [2][3]. Market Segmentation - The company's export business grew significantly, accounting for 25% of total revenue, with a year-on-year increase of 27.46%, while domestic market revenue declined by 7.25 percentage points [2]. - In 2024, domestic and foreign market revenues were approximately 6.47 billion yuan and 2.13 billion yuan, respectively, with domestic revenue down 6.4% and foreign revenue up 27.46% [3]. Cost Structure - The company experienced an increase in "three expenses" (sales, management, and financial expenses), with total expenses reaching 1.87 billion yuan, 463 million yuan, and 309 million yuan, respectively, marking increases of 6.35%, 9.59%, and 164.95% [4]. - The rise in expenses was attributed to increased brand promotion, online sales costs, employee compensation, and interest expenses [4]. Industry Dynamics - The mattress industry in China is characterized by a large number of small companies, with increasing competition among leading brands [5]. - The company is focusing on the sleep technology sector, transitioning from traditional manufacturing to technology-driven products, aiming for differentiation [5][6]. Future Strategy - The company plans to deepen its focus on the sleep technology sector, enhancing sales capabilities, quality control, cost reduction, and innovation [6]. - The mattress industry is expected to accelerate towards smart and health-oriented products, driven by consumer demand for technology and personalized experiences [6].

证券代码：300639 证券简称：凯普生物 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 ☑分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | | 太平洋证券 谭紫媚 李啸岩；信达证券 曹佳琳；国盛证券 王震；国信 | | | 证券 贺东伟；中信证券 陈竹/宋硕/陈逸飞/李文涛；汇安基金 周冲； | | 参与单位名称及人 | 东证自营 王光宇；广州玄甲私募基金管理有限公司 董丛从；禾永投资 | | 员姓名 | 顾义河；深圳市尚诚资产管理有限责任公司 黄向前；长江养老保险股 | | | 份有限公司 邱宏斌；上海鹤禧私募基金管理有限公司 李峥嵘等。 | | 时间 | 2025 年 4 月 29 日 10:00-11:00 | | 地点 | 电话会议 | | 上市公司接待人员 | 董事兼副总经理谢龙旭先生、副总经理兼董事会秘书陈毅先生、财务总 | | 姓名 | 监李庆辉先生 | | | 一、2024 ...

Core Viewpoint - Baolingbao achieved significant growth in Q1 2025, with a revenue of 685 million yuan, a year-on-year increase of 24.23%, and a net profit of 50.36 million yuan, up 117.35%, both reaching historical highs for the period [1] Group 1: Financial Performance - The company's comprehensive gross profit margin increased to 13.65%, up 3.67% from the same period last year [1] - The gross profit margin for the three core products (prebiotics, dietary fiber, and sugar-reducing sweeteners) reached 18.36% [1] Group 2: Product Demand and Market Strategy - There is a growing demand for sugar-reducing sweeteners, with the company's revenue from these products increasing by approximately 96% in Q1 [2] - The revenue growth for specific products includes erythritol (up 123%), allulose (up 82%), and crystalline fructose (up 80%) [2] Group 3: Project Development and Innovation - The production lines for DHA algae oil, lactulose, and HMOs have been completed and are in trial production [2] - The company has initiated the expansion project for allulose and is actively advancing the approval process for HMOs and allulose [2] - In Q1 2025, the company received three invention patent authorizations and participated in multiple industry standard formulations [2] Group 4: Market Outlook and Strategic Focus - The health food market is expected to enter a golden development period, with increasing consumer demand for functional ingredients like prebiotics and dietary fiber [2] - The company aims to leverage its technological advantages and market position to optimize product structure and innovate, adopting a "small, fine, and agile" model to meet differentiated demands [2] - Baolingbao plans to expand its domestic and international markets by utilizing its global layout and brand strength [2]

强强联合：科技赋能大健康产业 温江现代服务业战区作为现代服务产业示范区，长期致力于促进服务业数字化转型与跨界融合。京润未 来此次合作，旨在整合政策、技术、市场资源，加速大健康产业与数字经济的深度结合，将为项目提供 完善的产业配套和试验场景，形成"科技+医疗+医药+健康"的创新模式。 京润未来董事长张兴民表示："此次合作是京润未来智能化升级的关键一步。此前，京润未来先后构建 了润心智慧云医大药房、御君方互联网医院、芳华未来医疗健康服务平台等业务板块，逐步形成以医药 批发、医药电商零售、互联网医疗、健康管理、中医教育等多元化健康产业发展布局。本次合作，京润 未来将依托温江现代服务业战区的资源支持和区位优势，以数字化手段持续深化医疗、医药、健康管理 等与AI、5G、区块链技术等融合，让更多人享受便捷、精准、普惠的健康服务，积极响应国家战略， 为"健康中国"、"智慧养老"不断贡献力量。" 三大核心板块：构建互联网+医疗大健康数字化生态 1.御君方互联网医院：让每一个国人都有家庭医生 2025年4月28日，北京京润未来科技有限公司与温江现代服务业战区签署了《京润未来科技西部总部项 目投资协议》，双方将共同推动大健康产业 ...